Publications

2022

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.

The Lancet. Oncology.23(5):650-658[DOI] 10.1016/S1470-2045(22)00158-9.[PMID] 35421369.

3 citations·PubMed·Publisher's Site

2022

Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.

European urology.82(3):273-279[DOI] 10.1016/j.eururo.2022.04.017.[PMID] 35577644.

6 citations·PubMed·Publisher's Site

2022

Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].

European urology.82(1):e18-e19[DOI] 10.1016/j.eururo.2022.04.004.[PMID] 35440417.

PubMed·Publisher's Site

2022

First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.

European urology oncology.5(4):377-387[DOI] 10.1016/j.euo.2022.04.009.[PMID] 35641398.

1 citations·PubMed·Publisher's Site

2022

Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.

European urology oncology.5(1):70-83[DOI] 10.1016/j.euo.2021.07.001.[PMID] 34353775.

4 citations·PubMed·Publisher's Site

2022

Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.

European urology oncology.():-[DOI] 10.1016/j.euo.2022.03.005.[PMID] 35410825.

6 citations·PubMed·Publisher's Site

2022

Sagittal Band Injury and Extensor Tendon Realignment.

The Orthopedic clinics of North America.53(3):319-325[DOI] 10.1016/j.ocl.2022.02.004.[PMID] 35725040.

PubMed·Publisher's Site

2022

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.

European urology.82(1):6-11[DOI] 10.1016/j.eururo.2022.02.010.[PMID] 35393158.

2 citations·PubMed·Publisher's Site

2021

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

JAMA oncology.7(4):555-563[DOI] 10.1001/jamaoncol.2020.7857.[PMID] 33599706.

37 citations·PubMed·Publisher's Site

2021

Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.

European urology.80(1):12-15[DOI] 10.1016/j.eururo.2021.02.021.[PMID] 33653635.

24 citations·PubMed·Publisher's Site

2021

Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.

European urology.79(2):307-315[DOI] 10.1016/j.eururo.2020.11.036.[PMID] 33293079.

14 citations·PubMed·Publisher's Site

2021

Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.

European urology.80(2):e51-e52[DOI] 10.1016/j.eururo.2021.05.009.[PMID] 34053780.

PubMed·Publisher's Site

2021

Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?

European urology.80(1):18-19[DOI] 10.1016/j.eururo.2021.04.034.[PMID] 33972095.

1 citations·PubMed·Publisher's Site

2021

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

ESMO open.6(3):100152-[DOI] 10.1016/j.esmoop.2021.100152.[PMID] 33984672.

4 citations·PubMed·Publisher's Site

2021

Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.

European urology.80(4):522-523[DOI] 10.1016/j.eururo.2021.06.023.[PMID] 34274134.

1 citations·PubMed·Publisher's Site

2020

Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review.

Clinical oncology (Royal College of Radiologists (Great Britain)).32(6):347-353[DOI] 10.1016/j.clon.2020.04.005.[PMID] 32389318.

4 citations·PubMed·Publisher's Site

2020

Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250].

European urology.78(1):e48-e50[DOI] 10.1016/j.eururo.2020.03.017.[PMID] 32446863.

5 citations·PubMed·Publisher's Site

2020

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

Annals of oncology : official journal of the European Society for Medical Oncology.31(3):442-[DOI] 10.1016/j.annonc.2020.01.002.[PMID] 32067690.

3 citations·PubMed·Publisher's Site

2020

Do Learning Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001 and 2015.

European urology oncology.3(6):773-779[DOI] 10.1016/j.euo.2018.12.008.[PMID] 31411979.

3 citations·PubMed·Publisher's Site

2020

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.

European urology.77(2):223-250[DOI] 10.1016/j.eururo.2019.09.035.[PMID] 31753752.

92 citations·PubMed·Publisher's Site

2020

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.

JCO precision oncology.4():882-897[DOI] 10.1200/PO.19.00388.[PMID] 35050761.

10 citations·PubMed·Publisher's Site

2020

Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.

Journal of bone oncology.25():100311-[DOI] 10.1016/j.jbo.2020.100311.[PMID] 32995252.

18 citations·PubMed·Publisher's Site

2020

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.

JAMA oncology.6(2):206-216[DOI] 10.1001/jamaoncol.2019.4097.[PMID] 31830233.

11 citations·PubMed·Publisher's Site

2020

Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.

European urology.77(2):260-268[DOI] 10.1016/j.eururo.2019.11.001.[PMID] 31843338.

32 citations·PubMed·Publisher's Site

2020

Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8.

European urology.77(6):e156-e157[DOI] 10.1016/j.eururo.2020.02.013.[PMID] 32169314.

PubMed·Publisher's Site

2020

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".

European urology oncology.3(4):412-419[DOI] 10.1016/j.euo.2020.05.003.[PMID] 32591246.

8 citations·PubMed·Publisher's Site

2020

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.

Lancet (London, England).396(10260):1413-1421[DOI] 10.1016/S0140-6736(20)31553-1.[PMID] 33002429.

131 citations·PubMed·Publisher's Site

2019

A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.

European urology oncology.2(3):294-301[DOI] 10.1016/j.euo.2019.02.001.[PMID] 31200844.

27 citations·PubMed·Publisher's Site

2019

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.

European urology.76(6):719-728[DOI] 10.1016/j.eururo.2019.08.006.[PMID] 31447077.

101 citations·PubMed·Publisher's Site

2019

Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.

Trials.20(1):294-[DOI] 10.1186/s13063-019-3322-7.[PMID] 31138292.

25 citations·PubMed·Publisher's Site

2019

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology.30(12):e3-[DOI] .[PMID] 27141017.

14 citations·PubMed·Publisher's Site

2019

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.

International journal of radiation oncology, biology, physics.104(4):809-818[DOI] 10.1016/j.ijrobp.2019.03.015.[PMID] 30885775.

21 citations·PubMed·Publisher's Site

2019

Muscarinic receptors regulate auditory and prefrontal cortical communication during auditory processing.

Neuropharmacology.144():155-171[DOI] 10.1016/j.neuropharm.2018.10.027.[PMID] 30352212.

5 citations·PubMed·Publisher's Site

2019

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.

European urology.76(1):73-81[DOI] 10.1016/j.eururo.2019.03.015.[PMID] 30910346.

79 citations·PubMed·Publisher's Site

2019

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.

European urology.76(1):115-124[DOI] 10.1016/j.eururo.2019.02.003.[PMID] 30826218.

131 citations·PubMed·Publisher's Site

2019

Radiotherapy for metastatic prostate cancer-Authors' reply.

Lancet (London, England).394(10201):830-[DOI] 10.1016/S0140-6736(19)31829-X.[PMID] 31498099.

PubMed·Publisher's Site

2019

The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.

European urology.75(3):e51-e52[DOI] 10.1016/j.eururo.2018.11.003.[PMID] 30454914.

18 citations·PubMed·Publisher's Site

2019

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

Trials.20(1):264-[DOI] 10.1186/s13063-019-3216-8.[PMID] 31138317.

30 citations·PubMed·Publisher's Site

2018

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

European urology oncology.1(6):449-458[DOI] 10.1016/j.euo.2018.06.004.[PMID] 31158087.

18 citations·PubMed·Publisher's Site

2018

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Lancet (London, England).392(10162):2353-2366[DOI] 10.1016/S0140-6736(18)32486-3.[PMID] 30355464.

638 citations·PubMed·Publisher's Site

2018

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

European urology.73(3):427-435[DOI] 10.1016/j.eururo.2017.06.021.[PMID] 28705540.

57 citations·PubMed·Publisher's Site

2018

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology.29(5):1249-1257[DOI] 10.1093/annonc/mdy071.[PMID] 29788164.

49 citations·PubMed·Publisher's Site

2017

'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial.

Annals of oncology : official journal of the European Society for Medical Oncology.28(10):2327-2330[DOI] 10.1093/annonc/mdx410.[PMID] 28961849.

13 citations·PubMed·Publisher's Site

2017

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

The New England journal of medicine.377(4):338-351[DOI] 10.1056/NEJMoa1702900.[PMID] 28578639.

972 citations·PubMed·Publisher's Site

2017

Abiraterone in Metastatic Prostate Cancer.

The New England journal of medicine.377(17):1696-7[DOI] 10.1056/NEJMc1711029.[PMID] 29069563.

19 citations·PubMed·Publisher's Site

2017

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

European journal of cancer (Oxford, England : 1990).84():88-101[DOI] 10.1016/j.ejca.2017.07.003.[PMID] 28800492.

96 citations·PubMed·Publisher's Site

2017

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).

BJU international.119(4):522-529[DOI] 10.1111/bju.13549.[PMID] 27256016.

12 citations·PubMed·Publisher's Site

2017

Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707-708.

European urology.72(1):e17-[DOI] 10.1016/j.eururo.2016.09.036.[PMID] 27720530.

PubMed·Publisher's Site

2017

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

European urology focus.3(6):606-614[DOI] 10.1016/j.euf.2017.01.010.[PMID] 28753849.

14 citations·PubMed·Publisher's Site

2017

Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.

Clinical trials (London, England).14(5):451-461[DOI] 10.1177/1740774517725697.[PMID] 28830236.

46 citations·PubMed·Publisher's Site

2016

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

The Lancet. Oncology.17(2):243-256[DOI] 10.1016/S1470-2045(15)00489-1.[PMID] 26718929.

276 citations·PubMed·Publisher's Site

2016

Cancer Drugs Fund requires further reform.

BMJ (Clinical research ed.).354():i5090-[DOI] 10.1136/bmj.i5090.[PMID] 27677636.

21 citations·PubMed·Publisher's Site

2016

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

JAMA oncology.2(4):493-9[DOI] 10.1001/jamaoncol.2015.5570.[PMID] 26794729.

51 citations·PubMed·Publisher's Site

2016

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

JAMA oncology.2(3):348-57[DOI] 10.1001/jamaoncol.2015.4350.[PMID] 26606329.

118 citations·PubMed·Publisher's Site

2016

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.34(22):2636-43[DOI] 10.1200/JCO.2016.66.9697.[PMID] 27298414.

65 citations·PubMed·Publisher's Site

2016

Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.

Clinical oncology (Royal College of Radiologists (Great Britain)).28(10):666-7[DOI] 10.1016/j.clon.2016.07.004.[PMID] 27477123.

4 citations·PubMed·Publisher's Site

2016

STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.

Lancet (London, England).388(10041):235-6[DOI] 10.1016/S0140-6736(16)31041-8.[PMID] 27479566.

3 citations·PubMed·Publisher's Site

2016

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

Health technology assessment (Winchester, England).20(53):1-288[DOI] 10.3310/hta20530.[PMID] 27434595.

19 citations·PubMed·Publisher's Site

2015

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

European urology.67(5):904-12[DOI] 10.1016/j.eururo.2014.08.076.[PMID] 25218582.

19 citations·PubMed·Publisher's Site

2015

Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).

BJU international.116(6):880-7[DOI] 10.1111/bju.13069.[PMID] 25639506.

30 citations·PubMed·Publisher's Site

2015

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology.26(8):1589-604[DOI] 10.1093/annonc/mdv257.[PMID] 26041764.

222 citations·PubMed·Publisher's Site

2015

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

European urology.67(6):1028-1038[DOI] 10.1016/j.eururo.2014.09.032.[PMID] 25301760.

269 citations·PubMed·Publisher's Site

2014

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.

BJU international.113(5b):E137-43[DOI] 10.1111/bju.12564.[PMID] 24219029.

28 citations·PubMed·Publisher's Site

2014

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

The Lancet. Oncology.15(9):975-85[DOI] 10.1016/S1470-2045(14)70240-2.[PMID] 24974051.

135 citations·PubMed·Publisher's Site

2014

Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?

BJU international.113(2):189-99[DOI] 10.1111/bju.12469.[PMID] 24112742.

9 citations·PubMed·Publisher's Site

2014

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

European urology.66(5):799-802[DOI] 10.1016/j.eururo.2014.05.038.[PMID] 24985962.

43 citations·PubMed·Publisher's Site

2014

Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

European urology.66(1):120-37[DOI] 10.1016/j.eururo.2014.02.038.[PMID] 24613684.

196 citations·PubMed·Publisher's Site

2014

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

The Lancet. Oncology.15(7):738-46[DOI] 10.1016/S1470-2045(14)70183-4.[PMID] 24836273.

323 citations·PubMed·Publisher's Site

2014

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.

Investigational new drugs.32(5):995-1004[DOI] 10.1007/s10637-014-0101-x.[PMID] 24771350.

47 citations·PubMed·Publisher's Site

2013

Alpha emitter radium-223 and survival in metastatic prostate cancer.

The New England journal of medicine.369(3):213-23[DOI] 10.1056/NEJMoa1213755.[PMID] 23863050.

2009 citations·PubMed·Publisher's Site

2013

Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trial.

Clinical oncology (Royal College of Radiologists (Great Britain)).25(5):318-20[DOI] 10.1016/j.clon.2013.01.005.[PMID] 23489869.

11 citations·PubMed·Publisher's Site

2013

Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial.

BJU international.111(5):697-9[DOI] 10.1111/bju.12087.[PMID] 23578233.

25 citations·PubMed·Publisher's Site

2013

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

European urology.63(4):717-23[DOI] 10.1016/j.eururo.2012.11.042.[PMID] 23206856.

95 citations·PubMed·Publisher's Site

2012

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

The Lancet. Oncology.13(5):549-58[DOI] 10.1016/S1470-2045(12)70088-8.[PMID] 22452894.

82 citations·PubMed·Publisher's Site

2012

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.

Trials.13():168-[DOI] 10.1186/1745-6215-13-168.[PMID] 22978443.

99 citations·PubMed·Publisher's Site

2011

Reflections on attempted Anglo-Japanese collaboration on STAMPEDE: a randomized controlled trial for men with prostate cancer.

International journal of urology : official journal of the Japanese Urological Association.18(8):553-4[DOI] 10.1111/j.1442-2042.2011.02783.x.[PMID] 21615523.

2 citations·PubMed·Publisher's Site

2010

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.

BJU international.106(7):966-73[DOI] 10.1111/j.1464-410X.2010.09638.x.[PMID] 20840318.

92 citations·PubMed·Publisher's Site

2009

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

Trials.10():39-[DOI] 10.1186/1745-6215-10-39.[PMID] 19519885.

96 citations·PubMed·Publisher's Site

2009

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.27(32):5431-8[DOI] 10.1200/JCO.2008.20.1228.[PMID] 19805692.

261 citations·PubMed·Publisher's Site

2009

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

European urology.55(5):1112-23[DOI] 10.1016/j.eururo.2008.11.002.[PMID] 19042080.

139 citations·PubMed·Publisher's Site

2009

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

BJU international.103(4):464-9[DOI] 10.1111/j.1464-410X.2008.08034.x.[PMID] 18990168.

63 citations·PubMed·Publisher's Site

2008

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

Critical reviews in oncology/hematology.68 Suppl 1():S9-S22[DOI] 10.1016/j.critrevonc.2008.07.019.[PMID] 18723368.

24 citations·PubMed·Publisher's Site

2008

Speeding up the evaluation of new agents in cancer.

Journal of the National Cancer Institute.100(17):1204-14[DOI] 10.1093/jnci/djn267.[PMID] 18728279.

92 citations·PubMed·Publisher's Site

2008

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

Clinical oncology (Royal College of Radiologists (Great Britain)).20(8):577-81[DOI] 10.1016/j.clon.2008.07.002.[PMID] 18760574.

36 citations·PubMed·Publisher's Site

2007

Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).

Journal of the National Cancer Institute.99(10):765-76[DOI] .[PMID] 17505072.

82 citations·PubMed·Publisher's Site

2006

The changing pattern of management for hormone-refractory, metastatic prostate cancer.

Prostate cancer and prostatic diseases.9(3):221-9[DOI] .[PMID] 16801939.

13 citations·PubMed·Publisher's Site

2005

Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study.

Clinical oncology (Royal College of Radiologists (Great Britain)).17(4):217-8[DOI] .[PMID] 15997913.

7 citations·PubMed·Publisher's Site

2004

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

The New England journal of medicine.351(15):1502-12[DOI] .[PMID] 15470213.

4256 citations·PubMed·Publisher's Site

2000

Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer.

European urology.38(3):279-86[DOI] .[PMID] 10940701.

23 citations·PubMed·Publisher's Site

Show More